| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate |
2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf3f2f5e5f22cc0f8e7d7675db9b04a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d6be134708b065b3adb1095fc5f26aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76f2bd75ec5ba1bdcb10cd0e3f3ec2e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e0ea6512115355f477811bc2b2154a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_914b1fc0727f18807386d94c9020038c |
| publicationDate |
2022-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11467169-B2 |
| titleOfInvention |
Inflammatory biomarkers for predicting responsiveness to FGF-18 compound |
| abstract |
The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects. |
| priorityDate |
2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |